Kalaris Therapeutics, Inc. (KLRS) › Operating IncomeKalaris Therapeutics, Inc. (KLRS) — Operating IncomeAnnual figures by period end, from SEC filings.2019-12-31: -$26.70M2020-12-31: -$71.31M2021-12-31: -$169.82M2022-12-31: -$171.20M2023-12-31: -$199.90M2024-12-31: -$51.73M2025-12-31: -$46.15M-$46.15M2019-12-31Operating Income (USD)2025-12-31Period endedOperating IncomeChange YoYSource filing2025-12-31-$46.15M—2026-03-17From 2025-01-012024-12-31-$51.73M—2026-03-17From 2024-01-012023-12-31-$199.90M—2025-03-07From 2023-01-012022-12-31-$171.20M—2024-03-15From 2022-01-012021-12-31-$169.82M—2023-02-15From 2021-01-012020-12-31-$71.31M—2022-02-10From 2020-01-012019-12-31-$26.70M—2021-02-12From 2019-01-01Other metrics: RevenueCost of RevenueGross ProfitNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)